2 results
Approved WMOCompleted
Part 1: To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.Part 2: evaluate long-term safety profile of BIIB033 as an add-on therapy in subjects with MS.
Approved WMOWill not start
To evaluate the safety and tolerability of single ascending doses of ABBV-47D11 in subjects hospitalized with COVID-19.